New Opportunities to Treat the T315I-Bcr-Abl Mutant in Chronic Myeloid Leukaemia: Tyrosine Kinase Inhibitors and Molecules that Act by Alternative Mechanisms

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|17|13|1220-1245

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.17, Iss.13, 2010-05, pp. : 1220-1245

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34+ cells

By Santucci Maria   Mancini Manuela   Corradi Valentina   lacobucci Ilaria   Martinelli Giovanni   Botta Maurizio   Schenone Silvia  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 876-878

Springer Publishing Company

Access to resources Recommend Favorite

Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib?

By Doggrell Sheila A   Christensen Anne-Marie  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 1, 2011-01 ,pp. : 157-163

Informa Healthcare

Access to resources Recommend Favorite

Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis

By Soverini Simona   Martinelli Giovanni   Rosti Gianantonio   Iacobucci Ilaria   Baccarani Michele  

Pharmacogenomics, Vol. 13, Iss. 11, 2012-08 ,pp. : 1271-1284

Future Medicine

Access to resources Recommend Favorite

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check

By O'Hare Thomas   Eide Christopher A   Deininger Michael W  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 6, 2008-06 ,pp. : 865-878

Informa Healthcare

Access to resources Recommend Favorite

Inhibitors of ABL and the ABL-T315I Mutation

By  

Current Topics in Medicinal Chemistry, Vol. 8, Iss. 10, 2008-07 ,pp. : 905-921

Bentham Science Publishers

Access to resources Recommend Favorite